LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 10 von insgesamt 23

Suchoptionen

  1. Artikel ; Online: Chimeric Antigen Receptor T Cells: Toxicity and Management Considerations.

    Owusu, Kent A / Schiffer, Molly / Perreault, Sarah

    AACN advanced critical care

    2022  Band 33, Heft 4, Seite(n) 301–307

    Mesh-Begriff(e) Humans ; Receptors, Chimeric Antigen ; T-Lymphocytes
    Chemische Substanzen Receptors, Chimeric Antigen
    Sprache Englisch
    Erscheinungsdatum 2022-12-02
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 2239949-5
    ISSN 1559-7776 ; 1559-7768
    ISSN (online) 1559-7776
    ISSN 1559-7768
    DOI 10.4037/aacnacc2022936
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  2. Artikel ; Online: Evaluation and Management of Seizures and Status Epilepticus.

    Ameli, Pouya Alexander / Ammar, Abdalla A / Owusu, Kent A / Maciel, Carolina B

    Neurologic clinics

    2021  Band 39, Heft 2, Seite(n) 513–544

    Abstract: Seizures are frequently triggered by an inciting event and result from uninhibited excitation and/or decreased inhibition of a pool of neurons. If physiologic seizure abortive mechanisms fail, the ensuing unrestrained synchronization of neurons-status ... ...

    Abstract Seizures are frequently triggered by an inciting event and result from uninhibited excitation and/or decreased inhibition of a pool of neurons. If physiologic seizure abortive mechanisms fail, the ensuing unrestrained synchronization of neurons-status epilepticus-can be life-threatening and is associated with the potential for marked morbidity in survivors and high medical care costs. Prognosis is intimately related to etiology and its response to therapeutic measures. Timely implementation of pharmacologic therapy while concurrently performing a stepwise workup for etiology are paramount. Neurodiagnostic testing should guide titration of pharmacologic therapies, and help determine if there is a role for immune modulation.
    Mesh-Begriff(e) Humans ; Seizures/diagnosis ; Seizures/therapy ; Status Epilepticus/diagnosis ; Status Epilepticus/therapy
    Sprache Englisch
    Erscheinungsdatum 2021-03-31
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Review
    ZDB-ID 1013148-6
    ISSN 1557-9875 ; 0733-8619
    ISSN (online) 1557-9875
    ISSN 0733-8619
    DOI 10.1016/j.ncl.2021.01.009
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  3. Artikel ; Online: Improving Post-procedure Outcomes With Clinical Care Pathway for Enteral Access.

    Miller, Samuel M / Abou-Azar, Sara / Owusu, Kent A / Judson, Benjamin L / Rhodes, Deborah / Morton, John M

    The American surgeon

    2023  Band 89, Heft 12, Seite(n) 6362–6365

    Abstract: Our health system introduced an enteral access clinical pathway (EACP) hoping to increase nutritionist consults and decrease presentation to the Emergency Department, readmission to the hospital, and overall hospital length of stay. We followed patients ... ...

    Abstract Our health system introduced an enteral access clinical pathway (EACP) hoping to increase nutritionist consults and decrease presentation to the Emergency Department, readmission to the hospital, and overall hospital length of stay. We followed patients with short-term access (STA), longterm access (LTA), and short-long-term conversions (SLT) seen in the six months prior to the EACP launch (baseline group) and the six months after (performance group). The baseline cohort consisted of 2,553 patients and the performance cohort of 2,419 patients. Those in the performance group were more likely to receive a nutrition consult (52.4% vs 48.0%, P < .01), less likely to re-present to the ED (31.9% vs 42.6%, P < .001), and less likely to be readmitted to the hospital (31.0% vs 41.6%, P < .001. These findings suggest that the EACP may increase the likelihood of both expert-driven nutritional support and effective discharge planning for hospitalized patients.
    Mesh-Begriff(e) Humans ; Length of Stay ; Critical Pathways ; Nutritional Status ; Nutritional Support ; Patient Discharge ; Emergency Service, Hospital ; Patient Readmission ; Retrospective Studies
    Sprache Englisch
    Erscheinungsdatum 2023-05-19
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 202465-2
    ISSN 1555-9823 ; 0003-1348
    ISSN (online) 1555-9823
    ISSN 0003-1348
    DOI 10.1177/00031348231177914
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  4. Artikel ; Online: Alcohol Withdrawal Syndrome in Neurocritical Care Unit: Nicotine Replacement Therapy and Thiamine Deficiency.

    Farrokh, Salia / Roels, Christina / Owusu, Kent A / Nelson, Sarah E / Cook, Aaron M

    Neurocritical care

    2021  Band 34, Heft 2, Seite(n) 707–708

    Mesh-Begriff(e) Humans ; Smoking Cessation ; Substance Withdrawal Syndrome/etiology ; Thiamine Deficiency/drug therapy ; Tobacco Use Cessation Devices
    Sprache Englisch
    Erscheinungsdatum 2021-01-05
    Erscheinungsland United States
    Dokumenttyp Letter ; Comment
    ZDB-ID 2381896-7
    ISSN 1556-0961 ; 1541-6933
    ISSN (online) 1556-0961
    ISSN 1541-6933
    DOI 10.1007/s12028-020-01168-y
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  5. Artikel: Narrative Review: Addressing Covid-19 Vaccine Concerns in Special and Vulnerable Populations.

    Owusu, Kent A / Effendi, Muhammad K / Thompson Bastin, Melissa L / Tirmizi, Samad / Lat, Ishaq / Ammar, Mahmoud A

    Hospital pharmacy

    2022  Band 57, Heft 4, Seite(n) 575–587

    Abstract: Public health advocates and healthcare professionals (HCPs) have been challenged with vaccine hesitancy and addressing misinformation. In order for HCPs and pharmacists, in particular, to serve as effective stewards of COVID-19 vaccine science in the ... ...

    Abstract Public health advocates and healthcare professionals (HCPs) have been challenged with vaccine hesitancy and addressing misinformation. In order for HCPs and pharmacists, in particular, to serve as effective stewards of COVID-19 vaccine science in the interest of the public good, it is imperative for HCPs to appreciate the various factors contributing to vaccine hesitancy and vaccine distrust. A PubMed search was performed and relevant articles on COVID-19 vaccine in populations of interest were included. Information from health agencies, such as the Centers for Disease Control and Prevention (CDC) as well as established professional health societies was incorporated for guidance. This review focuses on COVID-19 vaccine concerns in the populations of children, pregnancy and lactation, immunocompromised, and religious and ethnic disparities. We also discuss post emergency use authorization experience with respect to vaccine safety including annotations on Guillain-Barré Syndrome, myocarditis and pericarditis, and thrombosis with thrombocytopenia syndrome.
    Sprache Englisch
    Erscheinungsdatum 2022-01-19
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 1468893-1
    ISSN 0018-5787
    ISSN 0018-5787
    DOI 10.1177/00185787211066463
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  6. Artikel ; Online: Application of Cannabinoids in Neurosciences: Considerations and Implications.

    Owusu, Kent A / Saliba, Lina / Ammar, Abdalla A / Ammar, Mahmoud A / Mucksavage, Jeffrey

    Critical care nursing quarterly

    2020  Band 43, Heft 2, Seite(n) 216–231

    Abstract: Medicinal cannabinoid use continues to evolve across the United States, although legitimate federal recognition for medicinal purpose is lacking. Variability exists across states within the United States with respect to legislation, and health care ... ...

    Abstract Medicinal cannabinoid use continues to evolve across the United States, although legitimate federal recognition for medicinal purpose is lacking. Variability exists across states within the United States with respect to legislation, and health care institutions encounter challenges when patients present with a history of medicinal cannabinoid use. Emerging evidence in the field of neurosciences suggests a role of cannabinoids for neurologic medical conditions such as Parkinson disease, multiple sclerosis, and epilepsy. We aim to provide an overview of cannabinoids including a historical perspective, pharmacology, applications in neurosciences, and challenges in health care and academia. Knowledge of the appropriate role of cannabinoids in the clinical setting is essential for all health care practitioners including nursing.
    Mesh-Begriff(e) Cannabinoids/history ; Cannabinoids/pharmacology ; Cannabinoids/therapeutic use ; Epilepsy/therapy ; History, 19th Century ; History, 20th Century ; History, 21st Century ; History, Ancient ; Humans ; Medical Marijuana/therapeutic use ; Multiple Sclerosis/therapy ; Neurosciences ; Parkinson Disease/therapy ; United States
    Chemische Substanzen Cannabinoids ; Medical Marijuana
    Sprache Englisch
    Erscheinungsdatum 2020-02-21
    Erscheinungsland United States
    Dokumenttyp Historical Article ; Journal Article
    ZDB-ID 639095-x
    ISSN 1550-5111 ; 0887-9303
    ISSN (online) 1550-5111
    ISSN 0887-9303
    DOI 10.1097/CNQ.0000000000000303
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  7. Artikel ; Online: Alcohol Withdrawal Syndrome in Neurocritical Care Unit: Assessment and Treatment Challenges.

    Farrokh, Salia / Roels, Christina / Owusu, Kent A / Nelson, Sarah E / Cook, Aaron M

    Neurocritical care

    2020  Band 34, Heft 2, Seite(n) 593–607

    Abstract: Alcohol withdrawal syndrome (AWS) can range from mild jittery movements, nausea, sweating to more severe symptoms such as seizure and death. Severe AWS can worsen cognitive function, increase hospital length of stay, and in-hospital mortality and ... ...

    Abstract Alcohol withdrawal syndrome (AWS) can range from mild jittery movements, nausea, sweating to more severe symptoms such as seizure and death. Severe AWS can worsen cognitive function, increase hospital length of stay, and in-hospital mortality and morbidity. Due to a lack of reliable history of present illness in many patients with neurological injury as well as similarities in clinical presentation of AWS and some commonly encountered neurological syndromes, the true incidence of AWS in neurocritical care patients remains unknown. This review discusses challenges in the assessment and treatment of AWS in patients with neurological injury, including the utility of different scoring systems such as the Clinical Institute Withdrawal Assessment and the Minnesota Detoxification Scale as well as the reliability of admission alcohol levels in predicting AWS. Treatment strategies such as symptom-based versus fixed dose benzodiazepine therapy and alternative agents such as baclofen, carbamazepine, dexmedetomidine, gabapentin, phenobarbital, ketamine, propofol, and valproic acid are also discussed. Finally, a treatment algorithm considering the neurocritical care patient is proposed to help guide therapy in this setting.
    Mesh-Begriff(e) Alcoholism ; Benzodiazepines ; Humans ; Hypnotics and Sedatives/therapeutic use ; Reproducibility of Results ; Retrospective Studies ; Substance Withdrawal Syndrome/drug therapy ; Substance Withdrawal Syndrome/therapy
    Chemische Substanzen Hypnotics and Sedatives ; Benzodiazepines (12794-10-4)
    Sprache Englisch
    Erscheinungsdatum 2020-08-13
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Review
    ZDB-ID 2381896-7
    ISSN 1556-0961 ; 1541-6933
    ISSN (online) 1556-0961
    ISSN 1541-6933
    DOI 10.1007/s12028-020-01061-8
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  8. Artikel ; Online: DEXmedetomidine compared to PROpofol in NEurocritical Care [DEXPRONE]: A multicenter retrospective evaluation of clinical utility and safety.

    Owusu, Kent A / Kurczewski, Lisa / Armahizer, Michael J / Zichichi, Albert / Maciel, Carolina B / Heavner, Mojdeh S

    Journal of critical care

    2020  Band 60, Seite(n) 79–83

    Abstract: Purpose: Although guidelines recommend dexmedetomidine (DEX) or propofol (PRO) as preferred sedatives in critically ill adults, comparisons in neurocritical care (NCC) are limited. We aimed to evaluate the clinical utility and safety of DEX compared ... ...

    Abstract Purpose: Although guidelines recommend dexmedetomidine (DEX) or propofol (PRO) as preferred sedatives in critically ill adults, comparisons in neurocritical care (NCC) are limited. We aimed to evaluate the clinical utility and safety of DEX compared with PRO in NCC setting.
    Materials and methods: This retrospective, multicenter, observational cohort study conducted at three tertiary academic hospitals with Level 1 Trauma Center and Comprehensive Stroke Center designations, compared the clinical indication and safety of DEX vs PRO in patients in NCC setting.
    Results: 179 patients were included (94 DEX and 85 PRO), median age of 58, 49% were male (DEX) and 58% were male (PRO). PRO was more commonly used to manage agitation. DEX was more commonly used for facilitating extubation, alcohol withdrawal, and sedation during frequent neurologic assessments. Mean Glasgow Coma Scale scores were higher in DEX group (11 vs. 9; p = .04). The duration of either infusions, mechanical ventilation, and lengths of stay were similar. No difference was observed in hypotension or bradycardia rates. Death was significantly higher with PRO (DEX 10% vs. PRO 22%; p = .02).
    Conclusions: DEX and PRO were used for distinct indications in our cohort. Adverse effect profiles and clinical outcome, in the cohorts are largely similar.
    Mesh-Begriff(e) Adult ; Aged ; Bradycardia/chemically induced ; Critical Care/methods ; Critical Illness ; Dexmedetomidine/adverse effects ; Female ; Humans ; Hypnotics and Sedatives/adverse effects ; Hypotension/chemically induced ; Intensive Care Units ; Male ; Middle Aged ; Propofol/adverse effects ; Respiration, Artificial ; Retrospective Studies ; Treatment Outcome
    Chemische Substanzen Hypnotics and Sedatives ; Dexmedetomidine (67VB76HONO) ; Propofol (YI7VU623SF)
    Sprache Englisch
    Erscheinungsdatum 2020-07-24
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Multicenter Study ; Observational Study
    ZDB-ID 632818-0
    ISSN 1557-8615 ; 0883-9441
    ISSN (online) 1557-8615
    ISSN 0883-9441
    DOI 10.1016/j.jcrc.2020.07.021
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  9. Artikel ; Online: Andexanet Alfa Versus 4-Factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage.

    Ammar, Abdalla A / Ammar, Mahmoud A / Owusu, Kent A / Brown, Stacy C / Kaddouh, Firas / Elsamadicy, Aladine A / Acosta, Julián N / Falcone, Guido J

    Neurocritical care

    2021  Band 35, Heft 1, Seite(n) 255–261

    Abstract: Background/objective: There are limited data on the risks and benefits of using andexanet alfa (AA) in comparison with four-factor prothrombin complex concentrate (4F-PCC) to reverse factor Xa inhibitors (FXi) associated intracranial hemorrhage (ICH). ... ...

    Abstract Background/objective: There are limited data on the risks and benefits of using andexanet alfa (AA) in comparison with four-factor prothrombin complex concentrate (4F-PCC) to reverse factor Xa inhibitors (FXi) associated intracranial hemorrhage (ICH). We sought to describe our experience with AA or 4F-PCC in patients with oral FXi-related traumatic and spontaneous ICH.
    Methods: We conducted a retrospective review of consecutive adult patients with FXi-related ICH who received AA or 4F-PCC. FXi-related ICH cases included traumatic and spontaneous intracranial hemorrhages. Our primary analysis evaluated ICH stability on head computed tomography scan (CT), defined as a similar amount of blood from the initial scan at the onset of ICH to subsequent scans, at 6-h and 24-h post-administration of AA or 4F-PCC. For the subset of spontaneous intraparenchymal hemorrhages, volume was measured at 6-h and 24-h post-reversal. In secondary analyses, we evaluated good functional outcome at discharge, defined as a Modified Rankin Score of less than 3, and the incidence of thrombotic events after AA or 4F-PCC adminstration, during hospitalization.
    Results: A total of 44 patients (16 traumatic and 28 spontaneous ICH) with median age of 79 years [72-86], 36% females, with a FXi-related ICH, were included in this study. The majority of spontaneous ICHs were intraparenchymal 19 (68%). Twenty-eight patients (64%) received AA and 16 patients (36%) received 4F-PCC. There was no difference between AA and 4F-PCC in terms of CT stability at 6 h (21 [78%] vs 10 [71%], p = 0.71) and 24 h (15 [88%] vs 6 [60%], p = 0.15). In a subgroup of patients with spontaneous intraparenchymal hemorrhage, there was no difference in the degree of achieved hemostasis based on hematoma volume between AA and 4F-PCC at 6 h (9.3 mL [6.9-26.4] vs 10 mL [9.4-22.1], adjusted p = 0. 997) and 24-h (9.2 mL [6.1-18.8] vs 9.9 [9.4-21.1], adjusted p = 1). The number of patients with good outcome based on mRS on discharge were 10 (36%) and 6 (38%) in the AA and 4F-PCC groups, respectively (adjusted p = 0.81). The incidence of thromboembolic events was similar in the AA and 4F-PCC groups (2 [7%] vs 0, p = 0.53).
    Conclusion: In this limited sample of patients, we found no difference in neuroimaging stability, functional outcome and thrombotic events when comparing AA and 4F-PCC in patients with FXi-related ICH. Since our analysis is likely underpowered, a multi-center collaborative network devoted to this question is warranted.
    Mesh-Begriff(e) Adult ; Anticoagulants/adverse effects ; Blood Coagulation Factors/pharmacology ; Factor Xa ; Factor Xa Inhibitors/adverse effects ; Female ; Humans ; Infant, Newborn ; Intracranial Hemorrhages/chemically induced ; Intracranial Hemorrhages/drug therapy ; Male ; Recombinant Proteins ; Retrospective Studies
    Chemische Substanzen Anticoagulants ; Blood Coagulation Factors ; Factor Xa Inhibitors ; PRT064445 ; Recombinant Proteins ; prothrombin complex concentrates (37224-63-8) ; Factor Xa (EC 3.4.21.6)
    Sprache Englisch
    Erscheinungsdatum 2021-01-06
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 2381896-7
    ISSN 1556-0961 ; 1541-6933
    ISSN (online) 1556-0961
    ISSN 1541-6933
    DOI 10.1007/s12028-020-01161-5
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  10. Artikel ; Online: Andexanet Alfa: Considerations and Practical Applications.

    Owusu, Kent A / Effendi, Muhammad K / DeFilippo, Nicholas A / Reardon, David P / Ian Lee, Alfred

    Critical pathways in cardiology

    2019  Band 18, Heft 4, Seite(n) 200–206

    Mesh-Begriff(e) Blood Coagulation Factors/therapeutic use ; Factor Xa/therapeutic use ; Factor Xa Inhibitors/adverse effects ; Hemorrhage/chemically induced ; Hemorrhage/drug therapy ; Humans ; Pyrazoles/adverse effects ; Pyridones/adverse effects ; Recombinant Proteins/therapeutic use ; Rivaroxaban/adverse effects
    Chemische Substanzen Blood Coagulation Factors ; Factor Xa Inhibitors ; PRT064445 ; Pyrazoles ; Pyridones ; Recombinant Proteins ; prothrombin complex concentrates (37224-63-8) ; apixaban (3Z9Y7UWC1J) ; Rivaroxaban (9NDF7JZ4M3) ; Factor Xa (EC 3.4.21.6)
    Sprache Englisch
    Erscheinungsdatum 2019-11-26
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 2079676-6
    ISSN 1535-2811 ; 1535-282X
    ISSN (online) 1535-2811
    ISSN 1535-282X
    DOI 10.1097/HPC.0000000000000190
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang